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and the relatively low relative risk of 
“unexplained” eczema associated with 
CCB use, we would have expected only 
about half of the cases of “unexplained” 
eczema among CCB users to be due to 
the drug, with the remaining half of such 
cases not related to CCB use.
Potential additional issues concerning 
the robustness of the finding are related to 
case definition, selection of controls, and 
possible informational bias. Although I 
have a mental picture of the eruption 
based on the data presented, I am not 
sure it is a correct one. For the results 
to be clinically useful and replicable, a 
clearer definition of “cases” with more 
information about the extent, distribu-
tion, morphology, and perhaps pathology 
of the eruption would help us apply these 
findings more accurately. Comparison of 
the characteristics of “elderly” with unex-
plained eczema using CCBs, particularly 
those who recover with CCB withdrawal, 
with those of nonusers ascertained for the 
case–control study would be particularly 
informative.
In case–control studies, selection of 
appropriate controls is often challenging 
and a potential source of bias. Finding 
the “right” controls is particularly diffi-
cult when cases come from a specialized 
population. In this study, cases appear 
to be sicker than controls. Cases used 
more medications than controls, includ-
ing antiarrhythmia agents and nitrates. 
Although the association of these drugs 
with eczema did not reach statistical sig-
nificance, it approached that observed 
with CCBs. These observations raise the 
possibility that either underlying cardiac 
illness or multiple-drug use, rather than 
CCB use alone, may be responsible for 
some cases attributed to CCBs.
In my experience, obtaining and con-
firming data on chronic past drug use is 
very challenging. The steps the investi-
gators took to establish chronic drug use 
were comprehensive and likely to be 
impractical in the United States. A com-
parison of the drugs ascertained through 
each of the three methods used by the 
authors would be instructive. However, 
the prevalence of drug use in the study’s 
controls is consistent with that observed 
in other populations, suggesting that 
controls were well selected and infor-
mational bias was limited (Kaufman et 
al., 2002).
The authors have done an admirable 
job of convincing me that in about half of 
older individuals taking CCBs with new 
onset of an extensive and perhaps pho-
todistributed chronic eczematous erup-
tion not otherwise explained after care-
ful workup, the eruption is due to CCBs. 
How generalizable are these results to 
practice? The data presented suggest that 
CCBs are responsible for only about 15% 
of chronic, otherwise unexplained ecze-
ma in the elderly. The broad net required 
(5 academic centers and 35 practices 
over 2 years) to ascertain 102 cases sug-
gests that unexplained new-onset eczema 
is infrequent in this age group and may be 
even more infrequent in the community 
than in referral and specialist practices.
Given the apparent low prevalence 
of this problem, even among CCB users, 
and the difficulty of performing confirma-
tory studies as good as this one, I do not 
believe that further retrospective studies 
are needed. A further characterization of 
histopathologic characteristics of CCB-
related eruptions may be useful. Although 
better understanding of the mechanism(s) 
of these reactions would be of interest, 
the generalizability of such potential find-
ings to drug-related chronic skin condi-
tions is likely to be limited. Perhaps we 
should declare victory and go home 
knowing that Joly and colleagues’ clinical 
recommendations are sufficiently robust 
to inform practice and remind us that 
chronic as well as short-term use of drugs 
can cause some inflammatory eruptions.
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Specific cell markers for selective isolation and growth of cells from the lym-
phatic and vascular systems have increased our understanding of the structure–
function relationships of both systems. Using these markers, a subset of blood 
vessel endothelial cells (BECs) with the properties of lymphatic endothelial cells 
(LECs) has been identified in psoriasis and eczema. The differentiation potential 
of BECs and LECs in vivo and in vitro is reviewed.
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Of increasing interest in the pathology 
of inflammatory and fibrotic skin dis-
ease is a role for transformation of both 
blood vessel endothelial cells (BECs) 
and lymphatic endothelial cells (LECs) 
into new cell types. A transition during 
which epithelioid cells lose their polar-
ity and cohesiveness and transform into 
spindle-shaped cells that are more fibro-
blast- or myofibroblast-like is referred to 
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as epithelial-to-myofibroblast transition 
(EMT). This commentary reviews evi-
dence for EMT in postembryonic BECs 
and LECs.
In BEC culture, dermal microvascu-
lar endothelial cells isolated from either 
neonatal or adult skin maintain a typical 
epithelial cobblestone appearance and 
closely duplicate the morphology and 
ultrastructure of microvascular cells in 
intact blood vessels. In the presence of 
factors that maintain intracellular levels 
of cyclic AMP, BECs continue to express 
BEC-specific markers over extended 
periods in culture. When exposed tran-
siently to inflammatory cytokines (inter-
leukin-1 (IL-1), tumor necrosis factor-α 
(TNF-α)) or to phorbol esters, BECs 
lose tight junctions, increase perme-
ability, and convert reversibly to a more 
spindle-shaped morphology similar to 
that observed in an inflamed, activated 
endothelium. In contrast to short-term 
exposure to inflammatory cytokines, 
long-term stimulation with the same 
inflammatory mediators permanently 
transforms BECs to spindle-shaped cells. 
In permanently transformed BECs, mark-
ers that identify BECs (factor VIII, type 
IV, collagen, CD 31) are lost (Romero 
et al., 1997) and matrix proteins nor-
mally synthesized by myofibroblasts (α-
smooth muscle actin, type I collagen) 
are expressed (Chaudhuri et al., 2007). 
A balance between the activation of 
protein kinase A and the inhibition of 
protein kinase C has been shown to 
play a key role in the regulation of EMT 
in vitro (Bokhari et al., 2005).
Earlier studies by Gröger et al. (2004) 
demonstrated that exposure of BECs to 
IL-3 induces a new set of transformed 
BECs that is different from that follow-
ing exposure to IL-1. BECs acquire the 
LEC-specific markers prox-1 and podo-
planin and continue to express CD 31. 
In these earlier studies a constant expo-
sure to IL-3 was required to maintain a 
LEC-like phenotype. In vivo IL-3 stimu-
lates expression of the major histocom-
patibility complex class II and cytokine 
production and may play a role in lym-
phocyte trafficking in inflammatory 
skin disease.
In this issue Gröger et al. (2007) 
extend their earlier studies of BECs 
in vitro and describe a new subset of 
BECs, both in psoriasis and in eczema, 
that expresses markers found in LECs. 
They ask whether this subset of BECs 
was the type of differentiation of BECs 
that they had described previously in 
vitro (Gröger et al., 2004) or the con-
sequence of an unusual cytokine acti-
vation of BECs. A similar subset of 
BECs was not observed in urticaria in 
which inflammation is not prominent. 
To address this question, the investiga-
tors compared prodoplanin and LYVE-1 
expression both in cytokine-simulated 
LEC and BEC cell cultures and in organ 
cultures of normal adult skin. Organ cul-
tures of skin more closely simulate con-
ditions approximating those observed 
in vivo and minimize changes in cell 
culture that may not completely repre-
sent those in vivo. As shown by Gröger 
et al. (2007) in this issue, a similar sub-
set of BEC-expressing LEC markers was 
observed in BECs in organ culture. Of 
interest was the observation that in BEC 
cell culture, IL-3 and TNF-α induced 
prodoplanin and LYVE-1 in all BECs, 
not only in a subset of cells. These dif-
ferences, although not major, are most 
likely another example of the important 
influences of tissue environment, cul-
ture medium, and passage number on 
gene expression—factors that must be 
evaluated when using cell culture as an 
in vitro model of the vascular system.
In involved psoriatic skin, multiple 
studies have shown that the number of 
CD8+ T cells is increased in the papil-
lary dermis. This population expresses 
proinflammatory cytokines, and in the 
presence of these mediators a decrease 
in tight gap junctions would be expect-
ed. In agreement with in vitro observa-
tions, a loss in tight gap junctions has 
been described at the ultrastructural 
level in the psoriatic vasculature. As 
shown in confluent BEC monolayers 
(Bokhari et al., 2005), a marked increase 
in permeability occurs following expo-
sure to inflammatory cytokines and fur-
ther demonstrates a close relationship 
among inflammation, gap junctions, 
and EMT. It would also be of interest to 
determine whether uninvolved skin of 
patients with psoriasis, particularly from 
those with an active Koebner response, 
would show an increased expression 
of LEC markers in the same set of BECs 
observed in vivo following exposure 
to IL-3 and TNF-α. Methods to isolate 
endothelial cells from small biopsies 
of normal and pathologic skin samples 
have been described and would be suit-
able for both functional and molecular 
profile analysis.
In another inflammatory disorder 
(scleroderma), there is a strong cor-
relation among inflammation, the 
disappearance of blood vessels, and 
the appearance of myofibroblasts. A 
mechanism to explain these changes 
is not known at present, but, based on 
the evidence for the transformation of 
BECs into myofibroblasts by inflamma-
tory cytokines in vitro (Chaudhuri et al., 
2007) and by drugs that inhibit these 
changes (Karasek, 2007), the transfor-
mation of microvascular endothelial 
cells into myofibroblasts in vivo may 
be one way to interpret the pathologic 
changes observed in vivo. EMT in BECs 
isolated from patients with scleroder-
ma would be of interest in light of the 
strong potential for endothelial-to-myo-
fibroblast transformation induced by 
inflammatory cytokines.
In Kaposi’s sarcoma (KS) there is 
additional evidence for a major role for 
EMT in the genesis of spindle cells, both 
in vivo and in vitro. In vivo human her-
pesvirus 8 (HHV8) has been detected 
in all forms of KS, as well as in atypical 
endothelial cells, prior to spindle-cell 
development (Kennedy et al., 1998). In 
vitro HHV8 infection of normal BECs 
results in the rapid conversion of nor-
mal BECs to spindle-shaped cells that 
are morphologically similar to the spin-
dle-shaped cells induced by cytokines 
(Moses et al., 1999).
Finally, we might ask whether podo-
planin, a transmembrane glycoprotein 
that co-localizes with members of the 
ERM (ezrin, radixin, moesin) protein 
family, plays a more important role in 
BEC and LEC physiology and pathology 
than recognized previously. Podoplanin 
is upregulated in several types of exper-
imental and human tumors, including 
|
Blood vessel endothelial 
cells with lymphatic cell 
properties have been 
identified in psoriasis 
and eczema
commentary
2712 Journal of Investigative Dermatology (2007), Volume 127
squamous-cell carcinoma of the skin 
(Schacht et al., 2005). In other epitheli-
al cell types (e.g., canine kidney epithe-
lial cells), podoplanin induces EMT via 
activation of Rho A (Martin-Villar et al., 
2006). Because tight gap junctions are 
necessary to maintain BEC homeosta-
sis, upregulation of podoplanin expres-
sion by inflammatory cytokines in 
BEC and binding to ERM may activate 
kinases central to regulation of EMT in 
BECs and LECs. Additional studies of 
the effect of podoplanin on BEC and 
LEC structure and function would be 
of interest.
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